How significantly does Methandienone suppress HDL cholesterol, and how is this measured?

Oral 17α-alkylated androgens including Methandienone suppress HDL-C by 40–70 % from individual pre-cycle baseline values, as measured by enzymatic colorimetric lipid panels in pharmacological study cohorts. The reduction is driven by hepatic lipase overactivation in hepatocytes and scales with both daily dose and cycle length. Monitoring with a fasting lipid panel at baseline and at cycle week three provides objective, quantified data rather than subjective estimation.

Why does oral Methandienone affect LDL and HDL more severely than injectable testosterone?

The 17α-alkylation that enables oral bioavailability concentrates the compound's hepatic lipase-activating effect in the liver, where lipoprotein metabolism is regulated. Injectable non-alkylated testosterone bypasses first-pass hepatic extraction, reducing hepatic lipase stimulation per unit of circulating androgen. Comparative lipid-panel studies using enzymatic colorimetric assay report HDL reductions of 10–20 % for injectable testosterone versus 40–70 % for equivalent oral 17α-alkylated androgens.

What dietary and supplementation interventions help protect cardiovascular health during a Naposim cycle?

Pharmaceutical-grade omega-3 fatty acids at 3–4 g combined EPA and DHA daily — sourced from fish oil verified for peroxide value — are the primary evidence-backed intervention for attenuating hepatic lipase overactivation during oral androgen use. Structured aerobic exercise at moderate heart-rate intensity three to four times weekly supports reverse cholesterol transport. These measures should complement, not replace, lipid panel monitoring at the midpoint of every cycle.

How many tablets are in a Vermodje Naposim pack, and how does the count fit a cardiovascular-aware cycle?

Each Vermodje Naposim pack contains 100 tablets of 10 mg Methandienone. For cardiovascular-conscious practitioners running 20 mg per day, the pack covers exactly 50 days — sufficient to complete a standard four-week cycle with residual tablets for a structured taper, keeping cumulative hepatic lipase exposure within a time-bounded window that aligns with mid-cycle lipid panel scheduling at week three.

Can Vermodje Naposim tablets be split to reach a lower dose for cardiovascular risk reduction?

Splitting is mechanically possible but introduces API delivery variance that HPLC per-tablet content-uniformity testing does not account for, as quality-control methodology validates whole-unit integrity. For practitioners targeting lower daily intakes to reduce lipid impact, the 10 mg tablet denomination itself is the minimum certified whole-unit increment. Consistent whole-tablet dosing preserves the content-uniformity guarantee and gives reliable data when correlated against mid-cycle lipid panels. (2) angle_used

New Formula

Vermodje

Naposim 10mg/tab 100 Tabletten by Vermodje

Name: Naposim 10mg/tab 100 Tablets by Vermodje
Brand: Vermodje
SKU: ORA-METH-VER-026
Price: 21.00 EUR
Availability: InStock

Naposim by Vermodje is an orally active 17α-alkylated anabolic androgenic compound delivering 10 mg of Methandienone per tablet across a 100-tablet supply, formulated with cardiovascular lipid management as its defining clinical consideration. Each tablet is produced at Vermodje's Chișinău-licensed facility under GMP-aligned controls; HPLC content-uniformity testing and LAL endotoxin assay results are batch-coded to the specific production lot — a traceability structure that supports per-cycle laboratory monitoring of lipid and hepatic markers.

€21.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid nitrogen retention onset supports lean-mass preservation during caloric phases without requiring extended cycle duration
10 mg per-tablet denomination allows precise daily-intake calibration aligned with cardiovascular monitoring thresholds
100-tablet pack volume supports a complete four-to-five-week protocol with surplus tablets for a structured dose taper
Batch-traceable HPLC potency data enables closed-loop alignment between API content and lipid panel outcomes
Vermodje GMP-aligned manufacturing controls tablet-to-tablet API consistency critical for dose-correlated cardiovascular risk assessment
LAL endotoxin clearance results assigned per production lot support reliable safety documentation throughout the monitoring framework

Phase	dosage	Note
Entry Phase (Weeks 1–2)	10–15 mg/day	Establish individual lipid baseline via fasting enzymatic colorimetric panel before first tablet; lower starting dose limits initial hepatic lipase stimulus
Maintenance Phase (Weeks 3–4)	15–20 mg/day	Obtain mid-cycle lipid panel at week three; if HDL-C has fallen more than 50 % from baseline, reduce dose by one 10 mg tablet per day
Taper Phase (Days 36–42)	10 mg/day	Stepped reduction limits abrupt androgenic withdrawal while allowing hepatic lipase activity to begin normalising before cycle exit
Post-Cycle Recovery	0 mg Methandienone	Lipid panel reassessment within two weeks post-cycle; aerobic conditioning maintained at 3–4 sessions per week to support HDL regeneration via reverse cholesterol transport

Key takeaways

Monitor fasting lipid panels at baseline, mid-cycle week three, and post-cycle.
Expect HDL suppression of 40–70 % from pre-cycle baseline during oral Methandienone use.
Supplement daily with 3–4 g combined EPA and DHA to attenuate hepatic lipase overactivation.
Prioritise shorter cycle windows to limit cumulative cardiovascular lipid exposure.
Track resting blood pressure alongside cholesterol values throughout every Naposim cycle.

Methandienone and Cardiovascular Risk: What the Lipid Evidence Shows

Naposim (Vermodje) is a 17α-alkylated oral androgen whose cardiovascular profile is defined primarily by its unfavourable impact on circulating lipoproteins — an effect that operates through a distinct hepatic mechanism rather than through direct myocardial action. Methandienone suppresses HDL-C (high-density lipoprotein cholesterol) by upregulating hepatic lipase activity, an enzyme measured in plasma using colourimetric substrate assays; in controlled pharmacological studies, oral 17α-alkylated androgens reduce HDL-C by 40–70 % from individual pre-cycle baselines, with the magnitude correlating to daily dose and cycle duration. LDL-C (low-density lipoprotein cholesterol) rises concurrently, widening the atherogenic ratio. These two observations form the evidence base against which every Naposim cycle should be planned.

HDL Suppression Mechanism and Dose Dependency

Hepatic lipase drives the primary mechanism: Methandienone activates hepatic lipase gene transcription through androgen-receptor-mediated signalling in hepatocytes, accelerating HDL catabolism faster than the liver can regenerate HDL particles from apolipoprotein A-I precursors. Compared to injectable non-17α-alkylated androgens such as Testosterone Enanthate — which produce modest HDL reductions in the 10–20 % range — oral Methandienone delivers a disproportionately large HDL reduction per milligram of administered dose, a gap documented in comparative lipid-panel studies using enzymatic colorimetric methodology. The practical implication is that shorter cycles at lower daily intakes protect the lipid ratio more effectively than extended high-dose protocols.

Protective Measures and Monitoring Framework

Omega-3 fatty acids (EPA + DHA combined at 3–4 g per day using pharmaceutical-grade fish oil tested for peroxide value) attenuate hepatic lipase overactivation and modestly support HDL regeneration during oral androgen cycles, as documented in sports-cardiology intervention literature. Practitioners should obtain a full fasting lipid panel — including LDL-C, HDL-C, total cholesterol, triglycerides, and the TC:HDL ratio — by enzymatic colorimetric assay at baseline, at cycle week three, and within two weeks post-cycle. Aerobic conditioning at moderate intensity (three to four sessions per week, 30–45 minutes, measured by heart-rate-based zone targeting) independently supports HDL recovery during and after Methandienone use by upregulating reverse cholesterol transport. Blood pressure monitoring via automated oscillometric cuff at rest provides a complementary cardiovascular safety checkpoint alongside lipid values throughout the Naposim cycle.

Usage

Obtain a fasting lipid panel by enzymatic colorimetric assay — including LDL-C, HDL-C, total cholesterol, triglycerides, and TC:HDL ratio — within seven days before consuming the first Naposim tablet to establish individual pre-cycle cardiovascular baseline values.
Begin oral Methandienone at 10 mg per day for the first two weeks using one whole Naposim tablet per administration; whole-tablet intake preserves HPLC content-uniformity certification and delivers pharmacologically accurate API quantity for dose-to-outcome correlation.
Initiate pharmaceutical-grade omega-3 supplementation at 3–4 g combined EPA and DHA daily from cycle day one, using fish oil tested for peroxide value; continue without interruption through the post-cycle recovery phase.
Schedule a second fasting lipid panel at the end of week three; compare HDL-C and LDL-C against pre-cycle baseline values using the same assay methodology to ensure like-for-like data interpretation, and adjust daily Naposim intake if HDL suppression exceeds 50 % from baseline.
Measure resting blood pressure via automated oscillometric cuff at the same time of day — morning, pre-supplementation — at the start and end of each cycle week; record results alongside lipid panel data to build a complete cardiovascular monitoring log.
Complete a final fasting lipid panel within two weeks after the last Naposim tablet and maintain structured aerobic exercise at moderate intensity three to four sessions per week to support reverse cholesterol transport and HDL recovery during the post-cycle window.

Warnings

Contraindications: Naposim is contraindicated in individuals with pre-existing dyslipidaemia, established cardiovascular disease, hepatic impairment, or active hypertension. Persons with TC:HDL ratio above 5.0 at pre-cycle baseline should not initiate Methandienone use until lipid status has been normalised through dietary, pharmacological, or lifestyle intervention.

Side_Effects: Cardiovascular: HDL-C suppression of 40–70 % from baseline, LDL-C elevation, widening of the atherogenic ratio, and blood pressure increases mediated by fluid retention and sympathetic activation. Hepatic: ALT and AST elevation proportional to daily dose and cycle duration. Androgenic: oily skin, accelerated scalp hair thinning in genetically susceptible individuals. Estrogenic: aromatisation to 17α-methylestradiol may produce fluid retention contributing to cardiac preload.

Monitoring: A minimum of three fasting lipid panels — pre-cycle, mid-cycle at week three, and within two weeks post-cycle — by enzymatic colorimetric assay is the structured monitoring standard for cardiovascular safety during Naposim use. ALT, AST, total bilirubin, and GGT should accompany each lipid panel. Resting blood pressure should be recorded weekly via oscillometric cuff. Any HDL-C value more than 60 % below the individual's pre-cycle baseline warrants immediate cycle discontinuation.

PCT: SERM-based post-cycle therapy using Tamoxifen or Clomiphene should begin within 72 hours of the final Naposim tablet. A post-PCT lipid panel at week four of recovery confirms whether hepatic lipase activity has normalised sufficiently to restore cardiovascular marker values toward individual pre-cycle reference ranges before any further anabolic compound use is considered.

Frequently asked questions

How significantly does Methandienone suppress HDL cholesterol, and how is this measured?: Oral 17α-alkylated androgens including Methandienone suppress HDL-C by 40–70 % from individual pre-cycle baseline values, as measured by enzymatic colorimetric lipid panels in pharmacological study cohorts. The reduction is driven by hepatic lipase overactivation in hepatocytes and scales with both daily dose and cycle length. Monitoring with a fasting lipid panel at baseline and at cycle week three provides objective, quantified data rather than subjective estimation.
Why does oral Methandienone affect LDL and HDL more severely than injectable testosterone?: The 17α-alkylation that enables oral bioavailability concentrates the compound's hepatic lipase-activating effect in the liver, where lipoprotein metabolism is regulated. Injectable non-alkylated testosterone bypasses first-pass hepatic extraction, reducing hepatic lipase stimulation per unit of circulating androgen. Comparative lipid-panel studies using enzymatic colorimetric assay report HDL reductions of 10–20 % for injectable testosterone versus 40–70 % for equivalent oral 17α-alkylated androgens.
What dietary and supplementation interventions help protect cardiovascular health during a Naposim cycle?: Pharmaceutical-grade omega-3 fatty acids at 3–4 g combined EPA and DHA daily — sourced from fish oil verified for peroxide value — are the primary evidence-backed intervention for attenuating hepatic lipase overactivation during oral androgen use. Structured aerobic exercise at moderate heart-rate intensity three to four times weekly supports reverse cholesterol transport. These measures should complement, not replace, lipid panel monitoring at the midpoint of every cycle.
How many tablets are in a Vermodje Naposim pack, and how does the count fit a cardiovascular-aware cycle?: Each Vermodje Naposim pack contains 100 tablets of 10 mg Methandienone. For cardiovascular-conscious practitioners running 20 mg per day, the pack covers exactly 50 days — sufficient to complete a standard four-week cycle with residual tablets for a structured taper, keeping cumulative hepatic lipase exposure within a time-bounded window that aligns with mid-cycle lipid panel scheduling at week three.
Can Vermodje Naposim tablets be split to reach a lower dose for cardiovascular risk reduction?: Splitting is mechanically possible but introduces API delivery variance that HPLC per-tablet content-uniformity testing does not account for, as quality-control methodology validates whole-unit integrity. For practitioners targeting lower daily intakes to reduce lipid impact, the 10 mg tablet denomination itself is the minimum certified whole-unit increment. Consistent whole-tablet dosing preserves the content-uniformity guarantee and gives reliable data when correlated against mid-cycle lipid panels. (2) angle_used

Manufacturer

Vermodje SRL's research orientation within its oral androgenic tablet range is expressed through compound-specific formulation work rather than one-size-fits-all tablet architecture. For Naposim, the 10 mg API-per-tablet specification reflects a deliberate dose-engineering decision: the tablet unit is sized to serve cardiovascular monitoring-aware practitioners who need precise whole-unit incrementability when correlating daily intake against mid-cycle lipid panel outcomes. Quality accountability at the Chișinău facility is structured around per-batch traceability — HPLC content-uniformity data and LAL endotoxin clearance results are both coded to the specific Naposim production lot, so practitioners can cross-reference the confirmed API content of each tablet against their own laboratory monitoring records. This traceability architecture distinguishes Vermodje's oral product documentation model from manufacturers whose quality statements remain at the bulk-blend rather than the per-unit level.

Product details

Brand	Vermodje
Active ingredient	methandienone
Also known as	Dianabol, Methandrostenolon, D-Bol, Danabol, Naposim, Vermodje Dianabol
Strength	10 mg
Form	Tabletten
Pack size	100 pieces
Item number	ORA-METH-VER-026

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Danabol 10mg/tab 100 Tablets by Balkan Pharmaceuticals

Lab Tested

Danabol 10mg/tab 100 Tabletten by Balkan Pharmaceuticals

Danabol by Balkan Pharmaceuticals is an oral anabolic-androgenic steroid whose active compound, Methandienone (10 mg per tablet), functions as a modified testosterone derivative engineered to bind directly and with notable affinity to the androgen receptor (AR), driving rapid anabolic signalling at the genomic level. Its 17α-alkylated, 2,17-dimethyl structural scaffold distinguishes it from unmodified androgens by increasing receptor-interaction duration and conferring oral bioavailability. Quality assurance for every batch is anchored in two validated analytical checkpoints: HPLC quantification of active-ingredient potency and LAL endotoxin screening — performed under Balkan Pharmaceuticals' certified GMP framework.

€26.00

Pro-Dynabol 20mg/tab 50 Tablets by Beligas Pharmaceuticals

HPLC Verified

Pro-Dynabol 20mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Dynabol is an oral anabolic tablet delivering Methandienone at 20 mg per unit, distinguished by a rapid-absorption, short-duration pharmacokinetic profile that demands a structured intraday dosing schedule to maintain stable plasma concentrations. Each pack contains 50 tablets, providing a complete supply for a standard introductory or intermediate oral cycle. Batch-level potency is confirmed through HPLC analysis; every lot produced by Beligas Pharmaceuticals passes documented laboratory verification before release.

€35.00

Danabol 10mg/tab 100 Tablets by Body Research

Pharma Grade

Danabol 10mg/tab 100 Tabletten by Body Research

Body Research Danabol delivers Methandienone at 10 mg per tablet across a 100-tablet supply, specifically formulated to maximize the oral bioavailability that distinguishes tablet-based administration from injectable Methandienone variants. Oral Methandienone reaches systemic circulation through hepatic first-pass metabolism, which reduces its absolute bioavailability to roughly 50–72 % compared to the near-complete uptake seen with intramuscular injection — a pharmacological trade-off that makes tablet selection, dosing timing, and gastrointestinal conditions decisive factors. Quality is verified through independent HPLC-based potency assay and LAL endotoxin testing; every production batch released under WHO-aligned GMP protocols reflects Body Research's Pharma Grade standard.

€85.00

Anabol Tablets 5mg/tab 1000 Tablets by British Dispensary

Purity Tested

Anabol Tablets 5mg/tab 1000 Tabletten by British Dispensary

British Dispensary Anabol Tablets deliver Methandienone at a precision-dosed 5 mg per tablet — a low-unit format that makes incremental metabolic titration straightforward for experienced users tracking blood-glucose and nutrient-partitioning responses. Anabolic-androgenic activity from this compound is closely linked to shifts in glucose uptake, glycogen synthesis, and overall substrate utilisation, making metabolic monitoring an integral part of any responsible protocol. Quality assurance is built into every 1,000-tablet jar: HPLC-verified potency and LAL endotoxin testing are completed prior to release, with manufacturing conducted under GMP-certified conditions at British Dispensary's Thailand facility.

€85.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00